News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aerpio Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema


9/19/2012 10:06:25 AM

CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class human protein tyrosine phosphatase beta (HPTP├č) inhibitor that works to activate Tie2, a receptor on vascular endothelial cells which promotes vascular stability, preventing abnormal blood vessel growth and vascular leak.

Read at BioSpace.com

comments powered by Disqus
Aerpio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES